In the final portion of this roundtable discussion at the 2024 American Society of Clinical Oncology Annual Meeting, Eric Winer, MD, of the Dana-Farber Cancer Institute; Naval Daver, MD, of the University of Texas MD Anderson Cancer Center; and Yasmin Abaza, MD, of Northwestern University, discuss what acute myeloid leukemia (AML) treatment will look like in the future.
